167 related articles for article (PubMed ID: 32160201)
41. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
43. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
44. Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.
Jung W; Kim K; Moon BI
Breast Care (Basel); 2022 Dec; 17(6):561-566. PubMed ID: 36590151
[TBL] [Abstract][Full Text] [Related]
45. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
46. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
47. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
[TBL] [Abstract][Full Text] [Related]
48. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer.
Ollila DW; Brennan MB; Giuliano AE
Arch Surg; 1998 Jun; 133(6):647-51. PubMed ID: 9637465
[TBL] [Abstract][Full Text] [Related]
50. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Barbie TU; Ma C; Margenthaler JA
Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
[TBL] [Abstract][Full Text] [Related]
51. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
53. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
54. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Azim HA; Davidson NE; Ruddy KJ
Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
[TBL] [Abstract][Full Text] [Related]
55. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
56. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
57. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
[TBL] [Abstract][Full Text] [Related]
58. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
59. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
60. Adjuvant endocrine treatment in premenopausal early breast cancer.
Orlando L; Fedele P; Cinefra M; Sponziello F; Calvani N; Chetrì MC; Rizzo P; D'Amico M; Schiavone P; Portaluri M; Criscuolo M; Burlizzi S; Cinieri S
Oncology; 2009; 77 Suppl 1():9-13. PubMed ID: 20130426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]